Eli Lilly and Company

This healthcare pharmaceutical giant and biotech stock is best known for its insulin products. But the company also develops a wide range of drugs including treatments for oncology, immunology, neurodegeneration, and cardiovascular disease. This century-old healthcare company has a loaded pipeline of medications waiting for FDA approval that could catapult your portfolio to new heights.

$789.09
(as of Apr 3, 7:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Eli Lilly and Company

Stock Price
$789.09
Ticker Symbol
LLY
Exchange
NYSE

Industry Information for Eli Lilly and Company

Sector
Healthcare
Industry
Drug Manufacturers - General

Company Description for Eli Lilly and Company

Country
USA
Full Time Employees
47,000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Fundamentals for Eli Lilly and Company

Market Capitalization
$734,752,538,624
EBITDA
$19,268,300,800
Dividends per Share
$5.20
P/E Ratio
70.05
Forward P/E Ratio
35.21
Earnings per Share
$11.68
Earnings per Share Estimate Next Year
Profit Margin
23.51%
Shares Outstanding
897,988,992
Percent Owned by Insiders
0.16%
Percent Owned by Institutions
83.53%
52-Week High
52-Week Low

Technical Indicators for Eli Lilly and Company

50-Day Moving Average
200-Day Moving Average
RSI
37.31
25.33

Analyst Ratings for Eli Lilly and Company

Strong Buy
15
Buy
6
Hold
6
Sell
1
Strong Sell
0

News About Eli Lilly and Company

Apr 3, 2025, 10:48 AM EST
Biogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, BIIB080. See more.
Apr 3, 2025, 9:00 AM EST
Two factors often determine stock prices in the long run: earnings and interest rates. See more.
Apr 2, 2025, 6:03 PM EST
Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs. See more.
Apr 2, 2025, 4:32 PM EST
Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide. See more.